Poly(ADP-Ribose) Polymerase Inhibitor [EPC]

24331 reported adverse events

Drugs of this class: NIRAPARIB OLAPARIB

These side effects are most commonly reported by patients taking drugs of the Poly(ADP-Ribose) Polymerase Inhibitor [EPC] class:

# Side effect Count
0 NAUSEA 5187
1 FATIGUE 4565
2 CONSTIPATION 3220
3 DEATH 3126
4 PLATELET COUNT DECREASED 3085
5 MALIGNANT NEOPLASM PROGRESSION 2179
6 INSOMNIA 2161
7 OFF LABEL USE 1945
8 VOMITING 1883
9 ANAEMIA 1827
See all common reactions for Poly(ADP-Ribose) Polymerase Inhibitor [EPC]

Drugs of the Poly(ADP-Ribose) Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CARBOHYDRATE ANTIGEN 125 INCREASED 1747 0.6250
1 EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS 36 0.5070
2 CARBOHYDRATE ANTIGEN 125 8 0.5000
3 ACUTE ERYTHROID LEUKAEMIA 12 0.4138
4 OVARIAN CANCER RECURRENT 321 0.3943
5 BRCA2 GENE MUTATION 19 0.3725
6 BRCA1 GENE MUTATION 9 0.2308
7 RECURRENT CANCER 552 0.2010
8 SCAN ABNORMAL 43 0.1799
9 EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS WORSENED 132 0.1774
See all enriched reactions for Poly(ADP-Ribose) Polymerase Inhibitor [EPC]